在食道胃癌超越人类表皮生长因子受体-2的向剂
Eric Mehlhaff1, Devon Miller1, Johnathan D Ebben1
1Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA.
胃食道癌症是多样化的,但新的生物标志物,如CLDN18.2和向疗法显示出希望. 未来的研究将解决治疗中的生物标志物重叠,异质性和毒性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 胃食道癌表现出显著的解剖学和分子多样性,使治疗策略复杂化.
- 了解瘤分子形状对于推进治疗选择至关重要.
- 最近的进展已经确定了新的生物标志物和向剂.
研究的目的:
- 审查了解胃食道癌分子特征的进展.
- 突出临床开发中的新兴生物标志物和向疗法.
- 讨论将新疗法整合到临床实践中的挑战.
主要方法:
- 关于胃食道癌症研究近期进展的文献综述.
- 对针对性药物的正在进行的临床试验的分析.
- 讨论已识别的生物标志物及其治疗影响.
主要成果:
- CLDN18.2被确定为具有显著生物标志物,具有已证明的向治疗活性.
- 贝马里图祖马布和DKN-01是正在积极调查中的向药物之一.
- 目前正在进行的临床试验的有希望的结果表明了潜在的新治疗途径.
结论:
- 向疗法和生物标志物为治疗各种胃食道癌症提供了新的希望.
- 解决生物标志物重叠,瘤异质性和毒性对于成功的治疗整合至关重要.
- 持续的研究对于优化新药在治疗连续中的使用至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
